AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03148366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin based sequential therapy
Description: D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
Study NCT03148366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth quadruple therapy for 10 days (BQ)
Description: D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
Study NCT04780165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blephademodex
Description: During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
Study NCT02579213 — intervention group
Intervention type: OTHER
Intervention: observational study done only in women candidate for amniocentesis
Description: As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
Study NCT03178643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proguanil Oral Tablet
Description: Dosing of daily proguanil will be approximately 3mg/kg/day,
Study NCT03178643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)
Description: Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
Study NCT03178643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: 3) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½
Study NCT02347423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI
Study NCT02347423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV Vaccine SSI
Study NCT00876161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
Study NCT03916939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathy
Description: osteopathy treatment
Study NCT03916939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated osteopathy
Description: simulated osteopathic sessions
Study NCT03082118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vesair Bladder Control System
Description: Intravesical balloon
Study NCT00876161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Study NCT01242826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
Study NCT00720759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine + distributed treatment
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
Study NCT00720759 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: D-cycloserine + condensed treatment
Description: Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
Study NCT00575120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemia reperfusion
Description: reperfusion after a 15 min. lasting cuff induced arm ischemia
Study NCT00730275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
Study NCT00730275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: matching placebo
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
Study NCT02548598 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Description: This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
Study NCT00720759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + distributed treatment
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
Study NCT00720759 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + condensed treatment
Description: Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
Study NCT01034553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora A kinase inhibitor MLN8237
Description: Given orally
Study NCT01034553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT04646278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperemic stimuli
Description: Hyperemic simuli of coronary flow by adenosine or nicorandil injection
Study NCT02318940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: installation of Central venous catheter ultrasound guided
Study NCT02318940 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: central venous catheter
Description: installation of Central venous catheter landmark guided
Study NCT03523637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
Study NCT01449500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: Chewable tablet, one tablet/day for 28 days
Study NCT01449500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chewable tablet, one tablet per day for 28 days
Study NCT01107821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Engenex™ pump and Bio-Dome™ Wound Dressing
Description: Engenex™ pump and Bio-Dome™ Wound Dressing is used.
Study NCT00356408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2.
Study NCT01015547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study NCT01015547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of DMARDs
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study NCT01015547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate alone
Description: Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study NCT01010334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
Study NCT01010334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
Study NCT02100787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTears lubricating drops
Description: A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
Study NCT00911937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4mg and 8 mg tablets taken daily.
Study NCT00911937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham 4mg and 8 mg tables taken daily.
Study NCT00497107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT, Calcium Folinate, PSK
Study NCT00497107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT, Calcium Folinate
Study NCT01235221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-SR)
Description: 10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
Study NCT04075344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Infection control programme
Description: 12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
Study NCT01872962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin (Induction chemotherapy)
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study NCT01769963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research diet
Description: Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
Study NCT04265807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Remote Ischemic Conditioning
Description: A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
Study NCT01872962 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
Study NCT01872962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
Study NCT03783065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
Study NCT03783065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
Study NCT03783065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and pericardial devascularization
Description: Including splenectomy and pericardial devascularizaion under laparoscopy
Study NCT03783065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
Study NCT00700427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine hydrochloride
Description: Oral 40-100 mg/day
Study NCT04265807 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
Study NCT00670280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing intervention
Description: Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
Study NCT01537172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4053
Description: Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
Study NCT00670280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
Study NCT01537172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
Study NCT02634177 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Assay-guided treatment (AGT)
Description: The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
Study NCT02634177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: Subjects are treated-as-usual without the aid of the assay.
Study NCT00670280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care - Reduced Measurement
Description: Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
Study NCT00300755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole sodium enteric-coated spheroid
Description: pediatric spheroids taken daily x 8 weeks
Study NCT00700427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine hydrochloride
Description: Oral 40-100 mg/day
Study NCT00700427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral delivery of matching placebo
Study NCT03711331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FilmArray® Pneumonia panel plus
Description: Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
Study NCT03711331 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
Study NCT02067559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU Diary
Description: Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
Study NCT01303484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bi2muno® GOS
Description: 5.5g/day for 10 weeks
Study NCT01936675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Risk Score
Description: Patients in this arm will receive their genetic-informed risk for having a heart attack.
Study NCT03228771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRGF/ATV
Description: Atorvastatin loaded in PRGF fibrin scaffold
Study NCT03228771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV gel
Description: Atorvastatin loaded in methyl cellulose gel
Study NCT03493295 — intervention group
Intervention type: DRUG
Intervention: Levonogestrel IntraUterine System (LNG-IUS)
Description: At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
Study NCT02719496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBEROGAST
Study NCT02067559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
Study NCT03073239 — intervention group
Intervention type: GENETIC
Intervention: ALS patients genetic characterization
Description: Genetic findings in ALS patients
Study NCT03073239 — intervention group
Intervention type: OTHER
Intervention: ALS patients epidemiological caracterization
Description: Epidemiological characterization in ALS patients
Study NCT01867736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DRB
Study NCT01867736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA (POBA)
Study NCT04561895 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction
Description: investigation of DNA polymorphism in patients suffering from NAFLD
Study NCT01556451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Description: Zoster vaccine live
Study NCT03030001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody expressing mesothelin specific CAR-T cells
Description: Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
Study NCT01729299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Study NCT04357444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: ILT101
Description: Subcutaneous injections, once-daily administration for 10 consecutive days.